Key Points
- Director Christine Berni Silverstein sold 20,070 shares on Feb. 2 at an average price of $5.09 for $102,156.30, reducing her stake by 12.72% to 137,722 shares (about $701,005).
- Several hedge funds recently built positions (including AIGH Capital, Boone Capital, Geode, Aberdeen and Cable Car), and institutional investors now own 80.56% of Abeona Therapeutics stock.
- Analyst sentiment is mixed but tilted positive — four Buys vs. one Sell with an average rating of "Moderate Buy" and an average price target of $20.00 — and the company recently reported a quarterly EPS of -$0.10, beating estimates of -$0.27.
Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Christine Berni Silverstein sold 20,070 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $102,156.30. Following the transaction, the director directly owned 137,722 shares of the company's stock, valued at $701,004.98. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Abeona Therapeutics Stock Down 3.6%
Abeona Therapeutics stock opened at $5.08 on Thursday. The stock has a market cap of $275.29 million, a price-to-earnings ratio of 4.13 and a beta of 1.18. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54. The company's 50-day moving average price is $5.17 and its two-hundred day moving average price is $5.58.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. On average, analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.
Hedge Funds Weigh In On Abeona Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. AIGH Capital Management LLC bought a new position in Abeona Therapeutics in the 4th quarter valued at approximately $10,540,000. Boone Capital Management LLC bought a new stake in Abeona Therapeutics in the second quarter valued at approximately $7,126,000. Geode Capital Management LLC raised its stake in Abeona Therapeutics by 129.1% during the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company's stock worth $6,282,000 after buying an additional 623,243 shares during the last quarter. Aberdeen Group plc bought a new stake in shares of Abeona Therapeutics during the 4th quarter valued at about $3,248,000. Finally, Cable Car Capital LP acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $3,168,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on ABEO shares. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings reissued a "sell (d+)" rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Abeona Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $20.00.
Get Our Latest Stock Analysis on ABEO
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
